Quick Answer
CNBX Pharmaceuticals Inc. reported Total Revenue of $0.00 for fiscal year 2025.
CNBX Pharmaceuticals Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$130.1K -68.3% |
$410.2K +1269.1% |
$30.0K | $0.00 -100.0% |
$7.2K -27.3% |
| Net Income | -$314.0K +54.8% |
-$695.2K +81.3% |
-$3.71M +0.3% |
-$3.72M -16.6% |
-$3.19M +57.2% |
-$7.47M -759.1% |
| Diluted EPS | $0.00 +100.0% |
-$0.02 +95.2% |
-$0.42 +88.3% |
-$3.59 -17850.0% |
-$0.02 | — |
| Total Assets | $18.4K -41.3% |
$31.4K -93.7% |
$499.0K -38.5% |
$811.2K -73.7% |
$3.08M +38.7% |
$2.22M -85.4% |
| Cash and Equivalents | $15.1K -42.8% |
$26.4K -79.6% |
$129.7K +10.4% |
$117.5K -91.5% |
$1.39M +78.3% |
$777.6K +192.4% |
| Stockholders Equity | -$2.50M -0.7% |
-$2.48M -22.9% |
-$2.02M -223.6% |
$1.63M -9.6% |
$1.81M +2.3% |
$1.76M -88.0% |
| R&D Expense | $0.00 -100.0% |
$194.8K -54.9% |
$431.6K -63.5% |
$1.18M -33.2% |
$1.77M +5.3% |
$1.68M +9.0% |
| Operating Income | -$271.7K +53.4% |
-$583.1K +37.4% |
-$931.4K +68.5% |
-$2.95M -13.6% |
-$2.60M +14.6% |
-$3.04M +7.9% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 553.96M +1680.6% |
31.11M +37.6% |
22.61M +1725.5% |
1.24M -99.2% |
148.66M +10.1% |
135.08M +0.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | November 30, 2025 | $0.00 | — | — |
| Net Income | November 30, 2025 | -$113.7K | -231.0% | -90.4% |
| Diluted EPS | November 30, 2025 | $0.00 | +100.0% | — |
| Total Assets | November 30, 2025 | $11.2K | -50.0% | -39.5% |
| Cash and Equivalents | November 30, 2025 | $7.7K | -55.6% | -49.0% |
| Stockholders Equity | November 30, 2025 | -$2.57M | -2.3% | -3.1% |
| R&D Expense | May 31, 2025 | $0.00 | -100.0% | — |
| Operating Income | November 30, 2025 | -$64.0K | -73.7% | -58.5% |
| Gross Profit | February 28, 2025 | $0.00 | -100.0% | -100.0% |
| Shares Outstanding | November 30, 2025 | 753.20M | +2321.0% | +36.0% |
- CNBX Pharmaceuticals Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Net Income of -$314.0 thousand for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +54.8% in Net Income compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +100.0% in Diluted EPS compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Total Assets of $18.4 thousand for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed a decrease of -41.3% in Total Assets compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Cash and Equivalents of $15.1 thousand for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed a decrease of -42.8% in Cash and Equivalents compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Stockholders Equity of -$2.50 million for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed a decrease of -0.7% in Stockholders Equity compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported R&D Expense of $0.00 for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed a decrease of -100.0% in R&D Expense compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Operating Income of -$271.7 thousand for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +53.4% in Operating Income compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Gross Profit of $5.7 thousand for fiscal year 2017.
- CNBX Pharmaceuticals Inc. showed a decrease of -94.9% in Gross Profit compared to the prior fiscal year.
- CNBX Pharmaceuticals Inc. reported Shares Outstanding of 553.96 million shares for fiscal year 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +1680.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: